Oncosyne’s CTO and co-founder Peter W. Eide will present new data at AACR 2026 demonstrating how high-content imaging of patient-derived colorectal cancer tumoroids can reveal clinically relevant heterogeneity linked to drug activity and mechanism of action.
These findings highlight the power of functional precision oncology approaches to generate decision-relevant insight earlier in development, helping pharma and biotech teams prioritize candidates, explore combination strategies, and reduce translational uncertainty before clinical positioning in GI oncology programs.
This presentation marks an important step forward for Oncosyne and reflects continued progress in applying patient-derived tumoroid models to support smarter, earlier decisions in colorectal and pancreatic cancer drug development. 🔬✨
